In particular, our results validate the group of prolactinomas as a low-risk PT since the risk of recurrence was 3 times lower in patients with prolactin-secreting PT (all of them macroadenomas, since having a microprolactinoma was an exclusion criterion for our PIT-VALIDATION study) than in the other subtypes. The gene discussed is PRL; the disease is Microprolactinoma.